AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26008722 — intervention group
Group type: EXPERIMENTAL
Intervention: T2DM-normal VF
Number of subjects: 151
Study 23409290 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Spirit intervention plus optimized standard care
Number of subjects: 322
Study 23409290 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Spirit intervention
Number of subjects: 322
Study 23409290 — intervention group
Group type: COMPARATOR
Intervention: Optimized standard care alone
Number of subjects: 322
Study 22111822 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake assessment using a 4-day dietary recall
Number of subjects: 291
Study 22111822 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake assessment
Number of subjects: 291
Study 18996523 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-335 + rosuvastatin 10 mg
Number of subjects: 1445
Study 18996523 — intervention group
Group type: EXPERIMENTAL
Intervention: ABT-335 + rosuvastatin 20 mg
Number of subjects: 1445
Study 17026664 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant preparation applied to forearm skin
Number of subjects: 15
Study 17026664 — intervention group
Group type: COMPARATOR
Intervention: Control area (no antioxidant preparation)
Number of subjects: 15
Study 17026664 — intervention group
Group type: COMPARATOR
Intervention: Comparison with DermAnalyzer method
Number of subjects: 15
Study 15576014 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release lithium carbonate matrix tablets containing 450 mg LC with 15% CP
Number of subjects: 9
Study 15576014 — intervention group
Group type: COMPARATOR
Intervention: Sustained-release commercial tablet (Eskalith CR)
Number of subjects: 9
Study 11094787 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg/m3 zinc oxide inhalation for naive subjects on 1 or 3 days
Number of subjects: 0
Study 11094787 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc oxide inhalation for sheet metal workers on 1 day
Number of subjects: 0
Study 11094787 — intervention group
Group type: COMPARATOR
Intervention: Control furnace gas inhalation for sheet metal workers on another day
Number of subjects: 0
Study 9125668 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem extended-release 240 mg once daily for 8 weeks
Number of subjects: 30
Study 8385161 — intervention group
Group type: EXPERIMENTAL
Intervention: OPC-21268 10 mg
Number of subjects: 33
Study 8385161 — intervention group
Group type: EXPERIMENTAL
Intervention: OPC-21268 50 mg
Number of subjects: 33
Study 8385161 — intervention group
Group type: EXPERIMENTAL
Intervention: OPC-21268 300 mg, 3 times daily for 7 days
Number of subjects: 33
Study 8385161 — intervention group
Group type: EXPERIMENTAL
Intervention: OPC-21268 100 mg single doses
Number of subjects: 33
Study 8385161 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 3898834 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 61
Study 3898834 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 61
Study 3898834 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (Sucralfate + Cimetidine)
Number of subjects: 61
Study 3898834 — intervention group
Group type: COMPARATOR
Intervention: Control (Placebo)
Number of subjects: 61
Study 31240854 — intervention group
Group type: EXPERIMENTAL
Intervention: PlGF testing alongside a clinical management algorithm
Number of subjects: 11
Study 31240854 — intervention group
Group type: COMPARATOR
Intervention: Current standard care
Number of subjects: 11
Study 30129537 — intervention group
Group type: EXPERIMENTAL
Intervention: Right lateral position
Number of subjects: 63
Study 30129537 — intervention group
Group type: COMPARATOR
Intervention: Left lateral position
Number of subjects: 63
Study 30129537 — intervention group
Group type: COMPARATOR
Intervention: All positions
Number of subjects: 63
Study 27510395 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1 μg/kg over 10 minutes followed by a 0.5 μg/kg/hr infusion)
Number of subjects: 90
Study 27510395 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl (1.0 μg/kg over 1 minute followed by a 0.4 μg/kg/hr infusion)
Number of subjects: 90
Study 27510395 — intervention group
Group type: COMPARATOR
Intervention: Remifentanil (1.0 μg/kg over 1 minute followed by a 0.08 μg/kg/min infusion)
Number of subjects: 90
Study 25088285 — intervention group
Group type: EXPERIMENTAL
Intervention: Complicated grief (CG)
Number of subjects: 335
Study 25088285 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 335
Study 21127953 — intervention group
Group type: COMPARATOR
Intervention: Better mother-child interactions (measured by mother's responsiveness)
Number of subjects: 432
Study 20033417 — intervention group
Group type: EXPERIMENTAL
Intervention: Organically produced apples (1 kg)
Number of subjects: 49
Study 20033417 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventionally produced apples (1 kg)
Number of subjects: 49
Study 20033417 — intervention group
Group type: EXPERIMENTAL
Intervention: Organically produced apples (500 g/day for 4 weeks)
Number of subjects: 49
Study 20033417 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventionally produced apples (500 g/day for 4 weeks)
Number of subjects: 49
Study 20033417 — intervention group
Group type: COMPARATOR
Intervention: Control group (no apples)
Number of subjects: 49
Study 18525384 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 g of green tea
Number of subjects: 14
Study 18525384 — intervention group
Group type: COMPARATOR
Intervention: 125 mg of caffeine
Number of subjects: 14
Study 18525384 — intervention group
Group type: COMPARATOR
Intervention: hot water
Number of subjects: 14
Study 15994660 — intervention group
Group type: EXPERIMENTAL
Intervention: Locality based community hospital care
Number of subjects: 220
Study 15994660 — intervention group
Group type: COMPARATOR
Intervention: Care on a ward for elderly people in a district general hospital
Number of subjects: 220
Study 12783052 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise at 40% 1-RM
Number of subjects: 13
Study 12783052 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise at 60% 1-RM
Number of subjects: 13
Study 12783052 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercise at 80% 1-RM
Number of subjects: 13
Study 10570099 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise during dialysis (pedalling on a cycle for 5-20 min at submaximal workload followed by 10 min rest, total 60 min exercise)
Number of subjects: 11
Study 8735325 — intervention group
Group type: COMPARATOR
Intervention: Blood samples drawn from heparinized double-lumen Hickman catheters after discarding 5, 10, 15, 20, and 25 ml of blood.
Number of subjects: 20
Study 8735325 — intervention group
Group type: COMPARATOR
Intervention: Peripheral blood samples obtained simultaneously.
Number of subjects: 20
Study 1836921 — intervention group
Group type: EXPERIMENTAL
Intervention: SmithKline Beecham's recombinant DNA (SB rDNA) vaccine (Engerix‐B) at its adult dose of 20 micrograms
Number of subjects: 48
Study 1836921 — intervention group
Group type: COMPARATOR
Intervention: MSD rDNA vaccine
Number of subjects: 48
Study 6407361 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous morphine (IVm) - 10 mg of morphine sulfate in 10 ml of saline
Number of subjects: 10
Study 6407361 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine (Em) - 10 mg of morphine sulfate in 10 ml of saline
Number of subjects: 10
Study 31876670 — intervention group
Group type: EXPERIMENTAL
Intervention: Exergaming (EXE)
Number of subjects: 68
Study 31876670 — intervention group
Group type: EXPERIMENTAL
Intervention: Balance (BAL)
Number of subjects: 68
Study 31876670 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycling (CYC)
Number of subjects: 68
Study 31876670 — intervention group
Group type: EXPERIMENTAL
Intervention: Proprioceptive Neuromuscular Facilitation (PNF)
Number of subjects: 68
Study 31876670 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 68
Study 31064897 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive feeding regimen
Number of subjects: 131
Study 31064897 — intervention group
Group type: COMPARATOR
Intervention: Conservative feeding regimen
Number of subjects: 131
Study 30223206 — intervention group
Group type: EXPERIMENTAL
Intervention: Introspection on craving and affect questions
Number of subjects: 0
Study 30223206 — intervention group
Group type: COMPARATOR
Intervention: Food cues
Number of subjects: 0
Study 30223206 — intervention group
Group type: COMPARATOR
Intervention: Neutral cues
Number of subjects: 0
Study 26917660 — intervention group
Group type: EXPERIMENTAL
Intervention: GP triage
Number of subjects: 16711
Study 26917660 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse triage
Number of subjects: 16711
Study 26917660 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 16711
Study 25269764 — intervention group
Group type: EXPERIMENTAL
Intervention: Trigger Point Dry Needling (TrP DN)
Number of subjects: 94
Study 25269764 — intervention group
Group type: COMPARATOR
Intervention: Trigger Point Manual Therapy (TrP MT)
Number of subjects: 94
Study 22103789 — intervention group
Group type: EXPERIMENTAL
Intervention: LESS surgery
Number of subjects: 25
Study 22103789 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic surgery
Number of subjects: 25
Study 19669016 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone (0.1 mg.kg‐1)
Number of subjects: 126
Study 19669016 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (2.0 (1/4)g.kg‐1)
Number of subjects: 126
Study 19669016 — intervention group
Group type: COMPARATOR
Intervention: Placebo (NS)
Number of subjects: 126
Study 17468473 — intervention group
Group type: EXPERIMENTAL
Intervention: icodextrin-based dialysate
Number of subjects: 17
Study 17468473 — intervention group
Group type: COMPARATOR
Intervention: glucose-based dialysate
Number of subjects: 17
Study 15376501 — intervention group
Group type: EXPERIMENTAL
Intervention: Vocal jitter in high-risk near-term suicidal patients
Number of subjects: 30
Study 15376501 — intervention group
Group type: EXPERIMENTAL
Intervention: Glottal flow spectrum slope in high-risk near-term suicidal patients
Number of subjects: 30
Study 15376501 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum likelihood classifier combining vocal jitter and glottal flow spectrum
Number of subjects: 30
Study 11840802 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol
Number of subjects: 50
Study 11840802 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 9824519 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician and pharmacist teamwork approach
Number of subjects: 95
Study 9824519 — intervention group
Group type: COMPARATOR
Intervention: Standard medical care
Number of subjects: 95
Study 7523041 — intervention group
Group type: EXPERIMENTAL
Intervention: High vessel density in breast cancer patients
Number of subjects: 106
Study 7523041 — intervention group
Group type: EXPERIMENTAL
Intervention: Low microvessel density in breast cancer patients
Number of subjects: 106
Study 7523041 — intervention group
Group type: COMPARATOR
Intervention: Adenofibroma
Number of subjects: 106
Study 2643046 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (45 mg per square meter of body-surface area, given on alternate days for six months)
Number of subjects: 158
Study 2643046 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific treatment)
Number of subjects: 158
Study 29575037 — intervention group
Group type: EXPERIMENTAL
Intervention: PMBL® Tablet
Number of subjects: 152
Study 29575037 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study 27056845 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity intervention (12 weeks)
Number of subjects: 22
Study 27056845 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 22
Study 26335635 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV nosode (30c potency pills), administered orally once a week for 4 weeks
Number of subjects: 22
Study 26335635 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical pills), administered orally once a week for 4 weeks
Number of subjects: 22
Study 24096767 — intervention group
Group type: EXPERIMENTAL
Intervention: Frey procedure
Number of subjects: 64
Study 24096767 — intervention group
Group type: COMPARATOR
Intervention: Pylorus-preserving pancreatoduodenectomy (PD)
Number of subjects: 64
Study 21390330 — intervention group
Group type: EXPERIMENTAL
Intervention: Video communication with parent during separation episodes
Number of subjects: 0
Study 21390330 — intervention group
Group type: COMPARATOR
Intervention: Video communication with parent
Number of subjects: 0
Study 18309940 — intervention group
Group type: EXPERIMENTAL
Intervention: Anastrozole (1 mg/d)
Number of subjects: 197
Study 18309940 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (20 mg/d)
Number of subjects: 197
Study 16990386 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab (600 mg weekly for 4 weeks, followed by 900 mg one week later and then 900 mg every other week through week 26)
Number of subjects: 87
Study 16990386 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 16990386 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 87
Study 15316551 — intervention group
Group type: EXPERIMENTAL
Intervention: Smooth stainless steel ultrasonic tips
Number of subjects: 100
Study 15316551 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotary preparations
Number of subjects: 100
Study 15316551 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonically prepared teeth
Number of subjects: 100
Study 15316551 — intervention group
Group type: EXPERIMENTAL
Intervention: Sonic and ultrasonic devices
Number of subjects: 100
Study 15316551 — intervention group
Group type: EXPERIMENTAL
Intervention: Type of retrotip used
Number of subjects: 100
Study 11349171 — intervention group
Group type: EXPERIMENTAL
Intervention: Cesarean delivery in HIV-seropositive women
Number of subjects: 86
Study 11349171 — intervention group
Group type: COMPARATOR
Intervention: Cesarean delivery in HIV-seronegative women (Control)
Number of subjects: 86
Study 11349171 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine use
Number of subjects: 86
Study 11349171 — intervention group
Group type: EXPERIMENTAL
Intervention: Major complications in HIV-seropositive women
Number of subjects: 86
Study 11349171 — intervention group
Group type: COMPARATOR
Intervention: Major complications in HIV-seronegative women (Control)
Number of subjects: 86
Study 9426795 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation during the luteal phase
Number of subjects: 40
Study 9426795 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation during the follicular phase
Number of subjects: 40
Study 9426795 — intervention group
Group type: COMPARATOR
Intervention: Smoking cessation (both groups)
Number of subjects: 40
Study 8355458 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid infusion (Totamine, 6 to 8 mg/kg/min for 90 to 120 min)
Number of subjects: 18
Study 8355458 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid infusion (Totamine) with perindoprilat (2 mg i.v.)
Number of subjects: 18
Study 8355458 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindoprilat (2 mg i.v.) alone
Number of subjects: 18
Study 8355458 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid infusion (Totamine)
Number of subjects: 18
Study 8355458 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindoprilat (2 mg i.v.)
Number of subjects: 18
Study 2451409 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose bunazosin (3 mg/day for the first week followed by 4.5 mg/day for the next three weeks)
Number of subjects: 205
Study 2451409 — intervention group
Group type: EXPERIMENTAL
Intervention: Middle dose bunazosin (1.5 mg/day for the first week to 3.0 mg/day for the next three weeks)
Number of subjects: 205
Study 2451409 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose bunazosin (0.15 mg/day for the first week to 1.5 mg/day for the next three weeks)
Number of subjects: 205
Study 2451409 — intervention group
Group type: COMPARATOR
Intervention: Control group (0.125 mg/day for the entire four weeks)
Number of subjects: 205
Study 30071871 — intervention group
Group type: EXPERIMENTAL
Intervention: LC‐Plasma (100 billion cells of heat‐killed LC‐Plasma per day for 13 days)
Number of subjects: 51
Study 30071871 — intervention group
Group type: EXPERIMENTAL
Intervention: LC‐Plasma
Number of subjects: 51
Study 30071871 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 27068158 — intervention group
Group type: EXPERIMENTAL
Intervention: Recreational football training (FT: n = 10)
Number of subjects: 27
Study 24581059 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative messages
Number of subjects: 209
Study 24581059 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored messages
Number of subjects: 209
Study 24581059 — intervention group
Group type: COMPARATOR
Intervention: Tailoring
Number of subjects: 209
Study 23768813 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine/CDP-choline
Number of subjects: 43
Study 23768813 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 20595536 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab and Methotrexate (INF-MTX)
Number of subjects: 20
Study 20595536 — intervention group
Group type: COMPARATOR
Intervention: Placebo and Methotrexate (placebo-MTX)
Number of subjects: 20
Study 18762060 — intervention group
Group type: EXPERIMENTAL
Intervention: Stuttering Measurement Assessment and Training (SMAAT) program training
Number of subjects: 20
Study 18762060 — intervention group
Group type: COMPARATOR
Intervention: No training (Control group)
Number of subjects: 20
Study 16644023 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone (MX) therapy
Number of subjects: 20
Study 16644023 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLC)
Number of subjects: 20
Study 12729289 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplements 2 ng/kg/day (group IA)
Number of subjects: 150
Study 12729289 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron syrup 6 mg/kg/day (group II)
Number of subjects: 150
Study 12729289 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group IB)
Number of subjects: 150
Study 11220944 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal approach including spinal or spinal-epidural anesthesia, preoperative epidural opioid analgesics, and administration of drugs affecting NMDA receptors (ketamine, magnesium sulfate)
Number of subjects: 1912
Study 8973523 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhesus tetravalent rotavirus vaccine (RRV‐TV)
Number of subjects: 0
Study 8973523 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotype G1 monovalent rotavirus vaccine (RRV‐S1)
Number of subjects: 0
Study 8973523 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-vaccination neutralizing antibody titers to Wa
Number of subjects: 0
Study 8973523 — intervention group
Group type: COMPARATOR
Intervention: G1 breakthrough strains
Number of subjects: 0
Study 8973523 — intervention group
Group type: COMPARATOR
Intervention: Control strains isolated from placebo recipients
Number of subjects: 0
Study 1349112 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ofloxacin 400 mg twice daily
Number of subjects: 122
Study 1349112 — intervention group
Group type: COMPARATOR
Intervention: Parenteral combination antibiotics (amikacin 15 mg/kg daily, plus carbenicillin, cloxacillin, or piperacillin)
Number of subjects: 122
Study 3840755 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 22
Study 3840755 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine
Number of subjects: 22
Study 3840755 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 3840755 — intervention group
Group type: COMPARATOR
Intervention: Control (Vagotomized patients)
Number of subjects: 22
Study 30131229 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled repetitive 24‐hour levosimendan infusions (LEVO) at tailored doses (0.05‐0.2 μg/kg/min)
Number of subjects: 185
Study 27467714 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen (30 mg/day for 3 months)
Number of subjects: 100
Study 27467714 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 27467714 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen
Number of subjects: 100
Study 23914987 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducation plus Care Ambassador outreach
Number of subjects: 153
Study 23914987 — intervention group
Group type: COMPARATOR
Intervention: Care Ambassador outreach
Number of subjects: 153
Study 23914987 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 153
Study 23187015 — intervention group
Group type: EXPERIMENTAL
Intervention: Nintendo Wii Fit; used for a minimum of thirty minutes per day for five weeks
Number of subjects: 18
Study 23187015 — intervention group
Group type: COMPARATOR
Intervention: No intervention (five weeks without any intervention)
Number of subjects: 18
Study 20537626 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary hMG
Number of subjects: 122
Study 20537626 — intervention group
Group type: COMPARATOR
Intervention: Recombinant FSH plus recombinant LH (Pergoveris)
Number of subjects: 122
Study 18764999 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg letrozole
Number of subjects: 6
Study 18764999 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 16003671 — intervention group
Group type: EXPERIMENTAL
Intervention: Audio-biofeedback (ABF)
Number of subjects: 9
Study 16003671 — intervention group
Group type: COMPARATOR
Intervention: Control (unaffected participants)
Number of subjects: 9
Study 11856089 — intervention group
Group type: EXPERIMENTAL
Intervention: OAC250 group (omeprazole 20 mg, amoxicillin 1000 mg, clarithromycin 250 mg)
Number of subjects: 352
Study 11856089 — intervention group
Group type: EXPERIMENTAL
Intervention: OAC500 group (omeprazole 20 mg, amoxicillin 1000 mg, clarithromycin 500 mg)
Number of subjects: 352
Study 11856089 — intervention group
Group type: EXPERIMENTAL
Intervention: OTC group (omeprazole 20 mg, tinidazole 500 mg, clarithromycin 500 mg)
Number of subjects: 352
Study 10102732 — intervention group
Group type: EXPERIMENTAL
Intervention: Head-down tilt with balanced traction (HDT)
Number of subjects: 6
Study 10102732 — intervention group
Group type: COMPARATOR
Intervention: Horizontal bed rest (HBR)
Number of subjects: 6